Robert Blaustein, M.D., Ph.D., joins the Company as Chief Development Officer, responsible for leading EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, ...

The company also announced the appointment of Robert Blaustein, M.D., Ph.D., as Chief Development Officer, who will lead the development of EDG-7500, a novel cardiac sarcomere modulator currently ...

Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the company as chief development officer and the promotion of ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the ...

Ann & Robert H. Lurie Children’s Hospital of Chicago announced the appointment of Ron Blaustein, 43, as Chief Financial Officer, effective June 1, 2014. Mr. Blaustein succeeds Paula Noble, who ...

Robert Blaustein, M.D., Ph.D., joins the Company as Chief Development Officer, responsible for leading EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, ...

Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics. "These leadership changes signify our... Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage ...

BOULDER, Colo., January 22, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will ...